FRED HUTCHINSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: https://www.fredhutch.org

Clinical Trials

Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Phase 2

Completed

Conditions: Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Secondary Myelodysplastic Syndromes
Acute Myeloid Leukemia With Multilineage Dysplasia
Secondary Acute Myeloid Leukemia
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Del(5q)
Previously Treated Myelodysplastic Syndromes
Untreated Adult Acute Myeloid Leukemia
de Novo Myelodysplastic Syndromes

Interventions: Drug: tosedostat
Drug: decitabine
Drug: cytarabine

First Posted Date: 2012-03-30

Last Posted Date: 2017-02-15

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 34

Registration Number: NCT01567059

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Partnership for a Hispanic Diabetes Prevention Program

Not Applicable

Completed

Conditions: Diabetes
Pre-diabetes

Interventions: Behavioral: Home Health Party

First Posted Date: 2012-03-28

Last Posted Date: 2015-03-06

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 430

Registration Number: NCT01564797

PATH Partnering to Achieve Tobacco-free Health

Phase 1

Completed

Conditions: Smoking Cessation

Interventions: Other: Acceptance & Commitment Therapy (ACT)
Other: Cognitive Behavioral Therapy (CBT)

First Posted Date: 2012-02-16

Last Posted Date: 2016-06-17

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 450

Registration Number: NCT01533974

Locations: 🇺🇸
Group Health Cooperative, Seattle, Washington, United States

Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies

Phase 2

Completed

Conditions: Aggressive Non-Hodgkin Lymphoma
Blasts Under 5 Percent of Bone Marrow Nucleated Cells
Loss of Chromosome 17p
Recurrent Adult Acute Lymphoblastic Leukemia
Recurrent Childhood Acute Myeloid Leukemia
Recurrent Chronic Lymphocytic Leukemia
Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Recurrent Diffuse Large B-Cell Lymphoma
Recurrent Hodgkin Lymphoma
Recurrent Mantle Cell Lymphoma

Interventions: Drug: Atorvastatin Calcium
Drug: Cyclosporine
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Drug: Mycophenolate Mofetil
Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Procedure: Peripheral Blood Stem Cell Transplantation
Radiation: Total-Body Irradiation

First Posted Date: 2012-02-06

Last Posted Date: 2020-01-02

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 47

Registration Number: NCT01527045

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
Presbyterian - Saint Lukes Medical Center - Health One, Denver, Colorado, United States

Cervical Cancer Screening Among Hispanic Women

Not Applicable

Completed

Conditions: Cervical Cancer

Interventions: Behavioral: DVD
Behavioral: Promotora

First Posted Date: 2012-02-03

Last Posted Date: 2018-11-13

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 451

Registration Number: NCT01525433

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Improving Smoking Cessation Quitlines: Pilot Study of Acceptance Therapy

Not Applicable

Completed

Conditions: Smoking

Interventions: Behavioral: Acceptance Therapy (ACT)
Other: Cognitive Behavioral Therapy (CBT)

First Posted Date: 2012-02-03

Last Posted Date: 2014-05-26

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 121

Registration Number: NCT01525420

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation

Phase 2

Completed

Conditions: Malignant Neoplasm

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Atorvastatin Calcium
Procedure: Peripheral Blood Stem Cell Transplantation

First Posted Date: 2012-02-03

Last Posted Date: 2017-08-17

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 83

Registration Number: NCT01525407

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
Stanford University Hospitals and Clinics, Stanford, California, United States
🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States

Alpha 1 Anti-Trypsin (AAT) in Treating Patients With Acute Graft-Versus-Host Disease GVHD)

Phase 1

Completed

Conditions: Graft-Versus-Host Disease (GVHD) Acute on Chronic

Interventions: Drug: Alpha 1-Proteinase Inhibitor, Human 1 MG [Glassia]

First Posted Date: 2012-02-01

Last Posted Date: 2018-10-30

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 20

Registration Number: NCT01523821

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma

Phase 1

Completed

Conditions: Plasma Cell Myeloma
Refractory Plasma Cell Myeloma

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Cyclosporine
Drug: Fludarabine Phosphate
Drug: Mycophenolate Mofetil
Procedure: Peripheral Blood Stem Cell Transplantation
Radiation: Total-Body Irradiation
Radiation: Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8

First Posted Date: 2012-01-02

Last Posted Date: 2019-12-09

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 15

Registration Number: NCT01503242

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Vitamin D and Adipose Tissue Inflammation

Not Applicable

Completed

Conditions: Vitamin D Deficiency
Obesity
Intestinal Permeability
Type 2 Diabetes Mellitus

Interventions: Dietary Supplement: Vitamin D3

First Posted Date: 2011-11-22

Last Posted Date: 2014-04-04

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 18

Registration Number: NCT01477034

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy